Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fp-EVs-msRNA4486
- Development stage
- Preclinical
- Lead developer
- Shanghai Children’s Hospital
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fp-EVs-msRNA4486 is an experimental therapeutic agent consisting of extracellular vesicles (EVs) derived from the commensal gut bacterium *Faecalibacterium prausnitzii* (Fp) that carry a specific microbial small RNA, msRNA4486. Developed by researchers at Shanghai Children’s Hospital, this asset is being investigated for the treatment of inflammatory bowel disease (IBD), specifically colitis. The drug works by inhibiting the activation of the MAPKs/NF-κB and NLRP3 inflammatory signaling pathways in intestinal epithelial cells and suppressing the differentiation of pro-inflammatory Th17 cells. In preclinical studies using DSS and TNBS-induced colitis models, Fp-EVs-msRNA4486 demonstrated the ability to reduce weight loss, improve disease activity index scores, and ameliorate colonic epithelial injury and inflammatory cell infiltration.
- Other names
- Extracellular Vesicle-derived msRNA4486 from Faecalibacterium Prausnitzii
02
Targets
NF-κBNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)MEK
Beyond the preview
Go deeper on Fp-EVs-msRNA4486.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fp-EVs-msRNA4486.